# Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

> **NCT00105287** · PHASE3 · COMPLETED · sponsor: **Cephalon** · enrollment: 100 (—)

## Conditions studied

- Pain
- Cancer

## Interventions

- **DRUG:** OraVescent fentanyl (OVF)

## Key facts

- **NCT ID:** NCT00105287
- **Lead sponsor:** Cephalon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-09
- **Final completion:** 2007-09
- **Target enrollment:** 100 (—)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00105287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00105287, "Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00105287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*